Andarine (S-4)
Muscle & Strength · SARM
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades Andarine (S-4) as D (2.9/10) based on very weak evidence, med benefit magnitude, and a unknown-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Added from WADA S1.
Studied, labeled, or reported-use context: No approved human dosing; gray-market protocols are not clinical dosing — Not FDA-approved; research chemical/gray market; WADA S1 prohibited; not individualized guidance.
What the evidence says
Added from WADA S1.2. Andarine is a distinct SARM from ostarine, ligandrol, RAD-140, S-23 and YK-11 already represented elsewhere. Human evidence is research-stage; this is not an approved supplement ingredient.
Mechanism
Nonsteroidal selective androgen receptor modulator developed for wasting and osteoporosis signals; gray-market users pursue lean-mass and recomposition effects.
Studied, labeled, or reported dose & route
No approved human dosing; gray-market protocols are not clinical dosing
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Andarine (S-4)'s effects?
- Read Off Label rates the evidence for Andarine (S-4) as Very Weak and the benefit magnitude as med, producing an overall grade of D (2.9/10). Added from WADA S1.
- What safety findings are reported for Andarine (S-4)?
- Andarine (S-4) has a unknown-high risk profile in the database. Unknown-High (vision disturbances reported anecdotally, HPG-axis suppression and liver/safety uncertainty as SARM class risks) Legal status: Not FDA-approved; research chemical/gray market; WADA S1 prohibited.
- What does the low Safety score for Andarine (S-4) represent?
- The Safety score is 3/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Andarine (S-4)?
- No approved human dosing; gray-market protocols are not clinical dosing This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Andarine (S-4) work?
- Nonsteroidal selective androgen receptor modulator developed for wasting and osteoporosis signals; gray-market users pursue lean-mass and recomposition effects.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.